Clinical Trials
37 trialsISG-ARTICLE
Italian Sarcoma Group
T-DIS
Centre Oscar Lambret
PIPER
Institut Bergonié
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
INVINCIBLE-3
Intensity Therapeutics, Inc.
TRABTRAP
Universität Münster
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
Sarcoma Oncology Research Center, LLC
TNT
Sarcoma Oncology Research Center, LLC
MANTRA
Rain Oncology Inc
YonSar
PharmaMar, Spain
TRASTS
Grupo Espanol de Investigacion en Sarcomas
OLATRASTS
Grupo Espanol de Investigacion en Sarcomas
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
HyperTET
Ludwig-Maximilians - University of Munich
NiTraSarc
University Medicine Greifswald
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Presage Biosciences
TOMAS
Italian Sarcoma Group
Trabectedin Maintenance Post 1st-line in STS
European Organisation for Research and Treatment of Cancer - EORTC
Metabol-STS
Centro di Riferimento Oncologico - Aviano
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Fred Hutchinson Cancer Center
TrObs
Italian Sarcoma Group
Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
University of Colorado, Denver
TSAR
Gustave Roussy, Cancer Campus, Grand Paris
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Xian-Janssen Pharmaceutical Ltd.
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
GOG Foundation
A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
Janssen Research & Development, LLC
Tabectedin to Treat Children and Adolescents With Cancer
National Institutes of Health Clinical Center (CC)
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS
Grupo Espanol de Investigacion en Sarcomas
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
Memorial Sloan Kettering Cancer Center
A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access
University of Texas Southwestern Medical Center